CoChat

Efficient identification of neoantigen-specific T-cell responses in advanced human ovarian cancer

Open access
Liu, Song, Matsuzaki, Junko, Wei, Lei, Tsuji, Takemasa, Battaglia, Sebastiano, Hu, Qiang, Cortes, Eduardo, Wong, Laiping, Yan, Li, Long, Mark, Miliotto, Anthony, Bateman, Nicholas W., Lele, Shashikant B., Chodon, Thinle, Koya, Richard C., Yao, Song, Zhu, Qianqian, Conrads, Thomas P., Wang, Jianmin, Maxwell, George L., Lugade, Amit A., Odunsi, Kunle · 2019 · Journal for ImmunoTherapy of Cancer
Cited by 85

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Abstract

Background Efficient identification of neoantigen-specific T-cell responses in epithelial ovarian cancer (EOC) remains a challenge. Existing investigations of spontaneous T-cell response to tumor neoepitope in EOC have taken the approach of comprehensive screening all neoantigen candidates, with a validation rate of 0.5–2%. Methods Whole-exome and transcriptome sequencing analysis of treatment-naive EOC patients were performed to identify neoantigen candidates, and the immunogenicity of prioritized neoantigens was evaluated by analyzing spontaneous neoantigen-specfic CD4+ and CD8+ T-cell responses in the tumor and/or peripheral blood. The biological relevance of neoantigen-specific T-cell lines and clones were analyzed by evaluating the capacity of autologous ovarian tumor recognition. Genetic transfer of T-cell receptor (TCR) from these neoantigen-specific T-cell clones into peripheral blood T-cells was conducted to generate neoepitope-specific T-cells. The molecular signature associated with positive neoantigen T-cell responses was investigated, and the impacts of expression level and lymphocyte source on neoantigen identification were explored. Results Using a small subset of prioritized neoantigen candidates, we were able to detect spontaneous CD4+ and/or CD8+ T-cell responses against neoepitopes from autologous lymphocytes in half of treatment-naïve EOC patients, with a significantly improved validation rate of 19%. Tumors from patients exhibiting neoantigen-specific T-cell responses exhibited a signature of upregulated antigen processing and presentation machinery, which was also associated with favorable patient survival in the TCGA ovarian cohort. T-cells specific against two mutated cancer-associated genes, NUP214 and JAK1, recognized autologous tumors. Gene-engineering with TCR from these neoantigen-specific T-cell clones conferred neoantigen-reactivity to peripheral T-cells. Conclusions Our study demonstrated the feasibility of efficiently identifying both CD4+ and CD8+ neoantigen-specific T-cells in EOC. Autologous lymphocytes genetically engineered with tumor antigen-specific TCR can be used to generate cells for use in the personalized adoptive T-cell transfer immunotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s40425-019-0629-6

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Cited by

See all 85

Metadata

Authors
Liu, S., Matsuzaki, J., Wei, L., Tsuji, T., Battaglia, S., Hu, Q., Cortes, E., Wong, L., Yan, L., Long, M., Miliotto, A., Bateman, N. W., Lele, S. B., Chodon, T., Koya, R. C., Yao, S., Zhu, Q., Conrads, T. P., Wang, J., Maxwell, G. L., Lugade, A. A., & Odunsi, K.
Venue
Journal for ImmunoTherapy of Cancer
Publisher
BMJ
Published
2019-06-20
Volume
7
Issue
1
Pages
156-156
ISSN
2051-1426 (ISSN-L)
OpenAlex
W2950859100
Cited by
85
References
23
FWCI
4.57
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficient identification of neoantigen-specific T-cell responses in advanced human ovarian cancer. https://app.cochat.ai/papers/10.1186/s40425-019-0629-6
The paper
Liu, S., Matsuzaki, J., Wei, L., Tsuji, T., Battaglia, S., Hu, Q., Cortes, E., Wong, L., Yan, L., Long, M., Miliotto, A., Bateman, N. W., Lele, S. B., Chodon, T., Koya, R. C., Yao, S., Zhu, Q., Conrads, T. P., Wang, J., . . . Odunsi, K. (2019). Efficient identification of neoantigen-specific T-cell responses in advanced human ovarian cancer. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1186/s40425-019-0629-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.